Earnings summaries and quarterly performance for BioAge Labs.
Executive leadership at BioAge Labs.
Board of directors at BioAge Labs.
Research analysts covering BioAge Labs.
Recent press releases and 8-K filings for BIOA.
BioAge Labs Presents Initial Clinical Data for Brain-Penetrant NLRP3 Inhibitor BIOA-102
BIOA
New Projects/Investments
Guidance Update
- BioAge Labs presented initial clinical results for its brain-penetrant NLRP3 inhibitor, BIOA-102, demonstrating that 60 mg once daily achieved IC90 target coverage in the brain and periphery, and 120 mg completely shut off IL-1 beta, with the drug being safe and well-tolerated.
- The company's next proof-of-concept (POC) study for BIOA-102 will primarily focus on CRP reduction in obese individuals with elevated cardiovascular risk factors, with obesity considered an upside.
- Upcoming data readouts include results from two obese MAD cohorts (BMI 32+, CRP >3) in the first half of 2026, followed by the initiation of a 12-week monotherapy study in obese patients mid-2026.
- BioAge Labs reported a cash balance of approximately $300 million and a runway of around three years, which covers current studies and taking APJ programs through Phase 1.
Dec 4, 2025, 6:30 PM
BioAge Labs Reports Positive Initial Clinical Data for NLRP3 Inhibitor and Outlines Future Development
BIOA
New Projects/Investments
Guidance Update
- BioAge Labs announced positive initial clinical results for its brain-penetrant NLRP3 inhibitor (102), demonstrating IC90 target coverage at 60 mg once daily and complete IL-1 beta shutdown at 120 mg, with the drug being safe and well-tolerated.
- A proof-of-concept study for 102 will target CRP reduction in obese individuals with elevated cardiovascular risk factors, with initial data from two MAD cohorts anticipated in the first half of 2026.
- The company maintains a cash balance of approximately $300 million, providing a runway of around three years.
- BioAge is actively developing a pipeline of additional NLRP3 inhibitors, including a second brain-penetrant compound and potent peripherally restricted compounds.
Dec 4, 2025, 6:30 PM
BioAge Labs Announces Positive Interim Phase 1 Data for BGE-102
BIOA
New Projects/Investments
- BioAge Labs, Inc. announced positive interim data from its ongoing Phase 1 clinical trial for BGE-102, a brain-penetrant small molecule NLRP3 inhibitor being developed for patients with cardiovascular risk factors.
- BGE-102 was well-tolerated across all dose levels evaluated and demonstrated strong target engagement with 90-98% suppression of IL-1β, alongside high brain penetration by exceeding target IC90 levels in cerebrospinal fluid (CSF) at Day 14.
- The company plans to expand the Phase 1 trial to include additional cohorts and anticipates initiating a Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in the first half of 2026, with Phase 2a data readout in the second half of 2026.
Dec 4, 2025, 2:05 PM
BioAge Labs Outlines Clinical Strategy Shift for NLRP3 Inhibitor
BIOA
New Projects/Investments
- BioAge Labs' lead program, an NLRP3 inhibitor, is currently in Phase 1 clinical trials, with data expected in the coming months. The company's unique NLRP3 molecule is structurally distinct from competitors, offering potential advantages in binding and safety.
- Following competitor Ventyx's data, BioAge is pivoting its Phase 2 trial design for its NLRP3 inhibitor to focus on cardiovascular risk factors and inflamed individuals at risk (e.g., obese patients with elevated CRP), rather than weight loss. Data from a longer-term study is expected by the end of 2026.
- The ongoing Phase 1 SADMAD study for the NLRP3 inhibitor aims to demonstrate safety, once-a-day dosing, and 90% IL-1 beta inhibition peripherally and in the brain.
- BioAge is also advancing APJ agonists (oral and injectable) with the goal to file an IND next year, aiming to address different segments of the obesity market with chemically distinct compounds to mitigate prior safety concerns.
- The company maintains earlier stage collaborations with Novartis and Lilly for additional targets from its platform.
Nov 17, 2025, 12:30 PM
BioAge Labs Updates on NLRP3 Inhibitor Program and Pipeline at Jefferies Conference
BIOA
New Projects/Investments
Guidance Update
- BioAge Labs' lead program, an NLRP3 inhibitor, is currently in Phase 1 clinical trials, with a data readout anticipated in the coming months.
- Following a competitor's clinical data showing profound CRP reductions (around 80%) but no weight loss, BioAge Labs now considers weight loss unlikely for its NLRP3 inhibitor in humans, despite positive preclinical weight loss data.
- The ongoing Phase 1 study aims to confirm safety, once-daily dosing, and 90% IL-1 beta inhibition; a subsequent three-month study focusing on cardiovascular risk factors is expected to yield data by end of 2026.
- BioAge Labs plans to file an IND next year for its APJ agonist programs, which include both oral and injectable strategies, targeting exercise mimetic mechanisms.
- The company also maintains earlier-stage collaborations with Novartis and Lilly for other platform-derived targets.
Nov 17, 2025, 12:30 PM
BioAge Labs Discusses NLRP3 and APJ Agonist Programs
BIOA
New Projects/Investments
Product Launch
- BioAge's lead NLRP3 inhibitor is in Phase 1, with data from a longer-term study on cardiovascular risk factors anticipated by end of 2026.
- The company is re-evaluating its NLRP3 clinical strategy, shifting focus from weight loss to cardiovascular risk factors and inflammatory mediators in obese patients with elevated CRP, influenced by competitor Ventyx's recent data showing 80% CRP reduction but no weight loss.
- BioAge plans to file an IND next year for its APJ agonist program, which features both oral and injectable candidates designed to enhance weight loss and preserve muscle mass, especially in combination with incretins.
- The company also maintains earlier-stage collaborations with Novartis and Lilly for additional targets from its platform.
Nov 17, 2025, 12:30 PM
BioAge Labs Reports Q3 2025 Financial Results and Clinical Progress
BIOA
Earnings
Guidance Update
New Projects/Investments
- BioAge Labs reported a net loss of $20.2 million, or $0.56 per weighted-average common share, for the third quarter ended September 30, 2025, alongside collaboration revenue of $2.1 million.
- As of September 30, 2025, the company had approximately $295.9 million in cash, cash equivalents, and marketable securities, which is projected to fund operations and capital expenses through 2029.
- The first participant was dosed in a Phase 1 clinical trial for BGE-102 in August 2025, with initial single ascending dose (SAD) data anticipated by year-end 2025. The company is also advancing its APJ agonist programs towards IND submissions in 2026.
Nov 6, 2025, 9:50 PM
Quarterly earnings call transcripts for BioAge Labs.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more